Table 1.
Features of 17 peripheral T cell lymphoma (PTCL) patients treated with DEVEC
| Naive | Relapsed/refractory | |
|---|---|---|
| Patients | ||
| Median age (range) | 83 years (70–87) | 71.5 years (56–85) |
| Male sex | 4/5 (80%) | 6/12 (50%) |
| Diagnosis | ||
| PTCL-NOS | 4 | 7 |
| PTCL-NOS Lennert type | 2 | |
| AITL | 1 | |
| NK/T nasal type | 1 | |
| ATLL/nodal | 1 | |
| tMF | 1 | |
| Stage III–IV | 5/5 | 11/12 |
| IPI 3–5 | 5/5 (100%) | 9/12 |
| PIT 3–4 | 5/5 (100%) | 8/12 |
| Previous chemo (median, range) | – | 1–3 (1) |
| DEVEC cycles (median, range) | 10 (7–38) | 8.5 (1–13) |
| ORR (%) | 4/5 (80%) | 8/12 (66%) |
| CR (%) | 1/5 (20%) | 3/12 (25%) |
PTCL-NOS not-otherwise-specified, AITL angioimmunoblastic T cell lymphoma, ATLL adult type T cell leukaemia lymphoma, tMF transformed mycosis fungoides, IPI international prognostic index, PIT prognostic index for T cell lymphoma